Content » Vol 92, Issue 4

Letter to the Editor

Patients’ Visual Analogue Scale: A Useful Method for Assessing Psoriasis Severity

Ingela Flytström1, Berndt Stenberg2, Åke Svensson3 and Ing-Marie Bergbrant1

Departments of Dermatology and Venereology, 1Sahlgrenska University Hospital, SE-413 45 Göteborg and 2Umeå University Hospital, Umeå, and 3Department of Dermatology, Malmö University Hospital, Malmö, Sweden. E-mail:

Accepted July 13, 2011.

The quality of life of patients with psoriasis can be severely diminished. The disease often affects life at a physical, social and emotional level (1). In clinical studies, a wide variety of assessment tools is used to evaluate the severity of psoriasis, but there is a lack of standardization (2). The introduction of quality of life (QoL) instruments has improved psoriasis evaluation, but there is a need for consensus in order to make valid comparisons between studies (3). The Psoriasis Area and Severity Index (PASI) is the most commonly used method to describe severity of psoriasis, and the Dermatology Life Quality Index (DLQI) is the most common method for measuring QoL in randomized controlled trials (4). The visual analogue scale (VAS) is an often-used tool to measure subjective phenomena, which has shown good reliability and validity in terms of assessment of pain (5).

The aim of this study was to compare the simple VAS instrument with the most-used instruments for measuring psoriasis severity and QoL.


Data from 68 patients with moderate-to-severe plaque psoriasis who participated in a 12-week randomized controlled trial comparing methotrexate and cyclosporin treatment effectiveness, QoL and side-effects, were used (6).

The PASI and patient VAS were used at baseline and at monthly intervals thereafter and the DLQI was used at baseline and after 8 and 12 weeks. The PASI was performed by blinded experienced assessors who had participated in a training course in assessment of the PASI prior to the study. The 100-mm VAS (ranging from zero (no complaints) to 100 (worst complaints)) was used for patients’ assessment of psoriasis activity at each visit. The statistical method used was the Spearman’s rank correlation coefficient test, non-parametric statistics.


There was a significant but modest correlation between the VAS and the DLQI at each visit (Fig. 1a), and also between the VAS and the PASI except at the baseline visit (Fig. 1b). A possible explanation for the lack of correlation at the baseline visit could be that some patients with lower PASI scores might still experience a major impact on QoL. Correlation, expressed as a percentage change from baseline to week 12, was found between the VAS and the PASI (Fig. 2a) and between the VAS and the DLQI (Fig. 2b). We suggest the VAS instrument should be used as a complement to the PASI and DLQI or as a single tool for assessing disease activity and QoL. The main advantage is that it takes only a few seconds to obtain a score, and imposes no inconvenience (7). One negative aspect might be the need for abstract thinking, which can make it difficult to understand and complete for some patient groups (8). Although further studies are needed to examine test-retest reliability and validity of the VAS in psoriasis assessment, we suggest that the VAS could be used for all psoriasis patients in everyday clinical practice.


Fig. 1. (a) Linear correlation between the visual analogue scale (VAS) and the Dermatology Life Quality Index (DLQI) at baseline (r = 0.39, p = 0.0011), week 8 (r = 0.31, p = 0.0111) and week 12 (r=0.55, p < 0.0001). (b) Linear correlation between the VAS and the Psoriasis Area and Severity Index (PASI) at baseline (r = 0.18, p = 0.1310), week 4 (r = 0.40,p = 0.0007; not shown in figure), week 8 (r = 0.57, p < 0.0001) and week 12 (r = 0.69, p < 0.0001).


Fig. 2. (a) Linear correlation of the visual analogue scale (VAS) and (a) the Psoriasis Area and Severity Index (PASI) and (b) the Dermatology Life Quality Index (DLQI) at week 12 expressed as a percentage change from baseline (a: r = 0.64, b: r = 0.65, p < 0.0001).

The authors declare no conflict of interest.


  • Krueger G, Koo J, Lebwohl M, Menter A, Stern R, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137: 280–284.
  • Naldi L, Svensson A, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, et al. Randomized clinical trials for psoriasis 1977–2000: the EDEN survey. J Invest Dermatol 2003; 120: 738–741.
  • Morsy H, Kamp S, Jemec GB. Outcomes in randomized controlled trials in psoriasis: what has changed over the last 20 years? J Dermatolog Treat 2007; 18: 261–267.
  • Garduno J, Bhosle MJ, Balkrishnan R, Feldman SR. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review. J Dermatol Treat 2007; 18: 223–242.
  • Li L, Liu X, Herr K. Postoperative pain intensity assessment: a comparison of four scales in Chinese adults. Pain Med 2007; 8: 223–234.
  • Flytström I, Stenberg B, Svensson A, Bergbrant IM. Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial. Br J Dermatol 2008; 158: 116–121.
  • Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med 1969; 62: 989–993.
  • Briggs M, Closs JS. A descriptive study of the use of visual analogue scales and verbal rating scales for the assessment of postoperative pain in orthopedic patients. J Pain Symptom Manage 1999; 18: 438–446.